AMD after cataract surgery unclear


The answer may be found in the masking effects of catract upon pre-existing disease

The association between cataract surgery and progression of age-related macular degeneration (AMD) still is unclear, said Dr Neil M. Bressler.

In light of this uncertainty, ophthalmologists can consider cataract surgery even in patients with AMD if the cataract affects vision and the patient's quality of life, Dr Bressler added.

Globally, cataracts are one of the leading causes of blindness, and according to the World Health Organization (WHO) "age-related cataract are responsible for 48% of world blindness." Additionally, WHO reports that in its 2010 estimates AMD is in the top three causes of blindness.1

Yet, there are questions as to the association between cataract surgery and the progression of AMD. According to Dr Bressler, clinical evidence shows no increase in risk for progression to advanced AMD after cataract surgery.

"If you think the cataract is visually significant to a patient, you should consider removing the cataract," he said. "There is no clear evidence that AMD eyes are at clinically important greater risk for progression to advanced AMD following cataract surgery."

Related Videos
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
© 2024 MJH Life Sciences

All rights reserved.